About

BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis and hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer, among several others.  BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.

 

MANAGEMENT TEAM

 

SCIENTIFIC ADVISORY BOARD